Table 1 Patient characteristics
From: PD1hi cells associate with clusters of proliferating B-cells in marginal zone lymphoma
Diagnosis | Histology | Age | Stage | LDH | TTFT | Alive | OS | Treatment | |
|---|---|---|---|---|---|---|---|---|---|
Extranodal | Periorbital | Diffuse | 62 | I | 282 | 1 | 0 | 62 | ISRT |
Extranodal | Periorbital | Foliicular architecture with colonisation of follicles | 59 | I | 257 | NA | 0 | 62 | W&W |
Nodal | Diffuse | 67 | IV | 329 | 1 | 0 | 70 | Rituximab+CHOP | |
Nodal | Diffuse | 67 | IV | 424 | 1 | 0 | 49 | Rituximab+FC | |
Extranodal | Periorbital | Residual germinal centres | 48 | IV | 237 | 3 | 0 | 30 | Rituximab+CVP + Rituximab maintenace |
Nodal | Diffuse | 61 | III | 227 | 5 | 0 | 36 | Rituximab+CHOP | |
Nodal | Diffuse | 73 | I | 248 | NA | 0 | 32 | W&W | |
Nodal | Diffuse | 73 | IV | 206 | 3 | 0 | 67 | ISRT | |
Splenic | Diffuse | 68 | I | ND | NA | 0 | 75 | Splenectomy | |
Splenic | Diffuse | 61 | IV | ND | 2 | 0 | 132 | Splenic RT; CVP; Radiotherapy | |
Splenic | Diffuse | 72 | IV | 290 | 2 | 1 | 1 | Chlorambucil | |
Nodal | Diffuse | 72 | IV | 277 | 1 | 1 | 1 | Rituximab+CVP | |
Nodal | Diffuse | 55 | IV | 234 | 9 | 0 | 62 | Obinutuzumab+CVP + Obinutuzumab maintenance | |
Extranodal | Diffuse | Diffuse | 74 | I | ND | NA | 0 | 31 | Lung lobectomy |
Extranodal | Diffuse | Diffuse | 63 | I | 202 | NA | 0 | 25 | W&W |